Sandoz: UK Public Sector Contracts Won & Awards
Companies House: Private Limited Company·Camberley, Surrey·Nationwide (UK)·Main market: Pharmaceutical products
Official UK PPONPNQL-1548-CYBZCompanies House01547204 ↗ · Active
Where they wini
i
155 awards (150 for a named lot, 97%, 5 for a whole procedure with no lot named) · top CPV classes, shares of all 155 awards. An award may cover more than one class.
3360 Pharmaceutical products154 awards · 99% · 149 awards naming a lot + 5 whole-procedure awards3369 Various medicinal products1 award · 1% · awards naming a loti
i
Where their buyers arei
i
ITL1 region of the buyer office · known for 119 of 119 awarded procedures · each procedure counts once
Bidding recordi
i
Procurement Act 2023 award notices name every bidder · 7 notices name this supplier, covering 12 lots since 6 Oct 2025 · observed bids, not an estimate
i
i
i
| Notice | Authority | Outcome | Bidders | Published |
|---|---|---|---|---|
| NHS National Generic Pharmaceuticals - Wave 16a | NHS England | appointedall 3 lots bid for | 125 | 9 Oct 2026 |
| NHS Branded Medicines Tranche A - NOFE and Midlands & East and Natalizumab for London & SOFE - 1 September 2026 | NHS England | appointedall 2 lots bid for | 25 | 21 Jul 2026 |
| NHS Branded Medicines - Tranche B - London & South of England - 1 September 2026 | NHS England | appointedall 2 lots bid for | 26 | 10 Jul 2026 |
| NHS National Framework for Transition Products (Nintedanib and Dalbavancin) | NHS England | not appointed | 14 | 24 Apr 2026 |
| NHS National Generic Pharmaceuticals - Wave 15c | NHS England | appointedall 2 lots bid for | 118 | 26 Feb 2026 |
| NHS National Framework for Denosumab Injection commencing 1st January 2026 | NHS England | not appointed | 13 | 4 Dec 2025 |
| NHS National Framework for Medical Retinal Vascular Treatments - 1 December 2025 | NHS England | undecided | 17 | 6 Oct 2025 |
Bidder names come from Procurement Act 2023 award notices, which list every bidder (from 2025). Older notices name no bidders, so earlier contests do not appear here. Latest ten notices shown.
Who they sell toi
i
Authorities named on this supplier’s published awards · ranked by distinct procedures · a framework or DPS adds one award record per appointed supplier
i
NHS & health94%(145 awards)
145 of 155 awards are NHS & health (94%).Type not classified6%(10 awards)
10 of 155 awards are Type not classified (6%).
| Authority | Procedures | Share | Award records | Last activity |
|---|---|---|---|---|
| NHS England | 51 | 42.9% | 77 | 27 Aug 2026 |
| The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS") | 32 | 26.9% | 60 | 9 Apr 2026 |
| NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) | 15 | 12.6% | 15 | 4 Jun 2026 |
| The NHS Commissioning Board (operating under the name of NHS England) | 6 | 5% | 9 | 7 Feb 2022 |
| Business Services Organisation Procurement and Logistics Service | 3 | 2.5% | 8 | 5 Jan 2026 |
| Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security Agency | 3 | 2.5% | 3 | 19 May 2023 |
| ATAMIS LTD | 3 | 2.5% | 3 | 7 Jul 2023 |
| eTenderwales | 2 | 1.7% | 2 | 17 Jun 2025 |
Share = of the 119 procedures with an award naming this supplier. Last activity = award date, or notice publication when no award date was published.
Contracts endingi
i
152 of 181 awards carry an end date, 56 estimated from the duration · not a retender forecast
| Contract | Ends | Published value |
|---|---|---|
| Dasatinib Tablets | 3 Jan 2027 estimated | £79,792 ceiling |
| Range Generic & Biosimilar Cancer Medicines (unranked) | 3 Jan 2027 estimated | £1,714,852 ceiling |
| Etanercept | 19 Jan 2027 estimated | £1,700,000 ceiling |
| Infliximab IV | 19 Jan 2027 estimated | £44,300,000 ceiling |
| Generic Drugs - Tablets & Capsules | 31 Jan 2027 | £2,801,383 |
| Generic Anti-Infective Drugs | 31 Jan 2027 | £213,548 |
| Wave 15a - Hospital Only Products (DNW & DLN regions) | 31 Jan 2027 | £1 ceiling |
| Wave 15b - Orals (plus non-parenteral) products | 31 Jan 2027 | £1 ceiling |
| Cancer Medicines (Group 2) | 31 Jan 2027 | £18,207,081 ceiling |
| NP49425 Generic and Biosimilar Transition Medicines | 28 Feb 2027 | £64,103,740 ceiling |
Soonest 10 of 35.
Recent awards
Latest 30 of 155 award records naming this supplier
Contracts Finder adds 26 more procedures won by this supplier, mostly below the Find a Tender threshold or from before 2025. Each is counted once beside any Find a Tender copy; they are in the totals, not in this list.
About this data
- One profile per supplier. Built from award and contract notices that name this supplier; different spellings and registration numbers of the same company are merged into this profile.
- Values are published values. The table mirrors what the notice published: framework ceilings and joint awards are labelled and never counted as this supplier's money, and † marks a value taken from the contract notice when the award published none. Only awards made to this supplier alone count towards its value, excluding VAT. It is not turnover.
- Regions in the buyer chart describe the buyer office, not where the work is delivered or the supplier’s registered address.
- Contract end dates. Published on 96 of 181 awards, estimated from the published duration on 56 more (marked “estimated”); those feed “Contracts ending”. Published values in that list come from either source; Contracts Finder figures are shown as published and stay out of this profile’s money totals.
- Source. Official UK public procurement notices (Find a Tender and Contracts Finder), reused under the Open Government Licence v3.0, updated through the day and rebuilt nightly. Not every figure uses both feeds, and each one shows how many records it rests on: see the methodology. Spotted something wrong? Tell us.